Popular Posts

FaceBook Fan Page

Counter

Powered By Cool Blog Tricks

OCTREOTIDE ACETATE(SANDOSTATIN) Adverse Effects Indications and Precautions

Indications:

Octreotide inhibits growth hormone secretions and glucagon, secretion,useful in the treatment of acromegaly,Zollinger-ellison syndrome,secretory diarrhea,carcinoid syndrome and GI endocrine tumors.

Doses & Administrations:
Adult: subcutaneous Acromegaly: 50 - 100 mcg SC 2 - 3 times daily. Gastrinoma: 200 mcg SC 2 times daily. Pancreatic Tumors: 100 - 600 mcg/ day SC in 2 - 4 divided doses. Small bowl fistula: 225 - 300 mcg/day in 3 divided doses. Intravenous; Zollinger- ellison syndrome as continuous infusion 25 mcg/hour. Maintenance : 100 mcg SC Twice daily.

Contra Indications:
Hypersensitivity to the drug.

Precautions:
Diabetic patient,repeated injection should be avoided, pregnancy,lactation,renal impairement and gall bladder abnormalities.

Pregnancy Status:
Category "B"

Renal Failure Doses:
Dose adjustment may be necessary in patients with severe renal failure requiring dialysis since half life of drug can be increased. Ref:Micromeix

Lactation Status:
Unknown.

Interactions:
Cyclosporin.

Adverse Effects:
Diarrhea, loose stools,nausea,abdominal discomfort, headache,dizziness,fatigue,weakness,sinus bradycardia, arrythmias,pneumonia,cold symptoms,injection site pain, hyperglycemia,hypoglycemia and galactorrhea.

Nursing Considerations:
IV DILUTION-----0 to 200 mcg/ 50 ml (@ 15-30 min) 600 mcg/ 250 ml (@ 25 mcg/hr) 1250 mcg/ 250 ml (@ 50 mcg/hr) Usually 25 to 50 mcg/ hr. Dilute in NS preferably, but acn also dilute in D5W *(Ref:Vancouver Hospital Health Sciences Center, Parenteral Drug Therapy Manual)
Anda baru saja membaca artikel yang berkategori Adverse Effects / indication / OCTREOTIDE ACETATE / Precautions dengan judul OCTREOTIDE ACETATE(SANDOSTATIN) Adverse Effects Indications and Precautions. Anda bisa bookmark halaman ini dengan URL https://medipub.blogspot.com/2011/05/octreotide-acetatesandostatin-adverse_31.html. Terima kasih!
Ditulis oleh: Unknown - Tuesday, 31 May 2011